3 terminated, 2 completed, 1 unknown. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Terminated 3, Completed 2, Unknown 1 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow Analgesics: new trials by email Literature Review of Analgesics trials Research Report on Analgesics
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder Lemborexant, Placebo, Buprenorphine-naloxone - Drug Interaction, Analgesics | Phase 1 / Phase 2 | Completed | Virginia Commonwealth University | 18 | 2021-05-03 | 2024-11-13 |
| Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM CYNK001-IV, CYNK001-IT - Astrocytoma, Grade IV, Giant Cell Glioblastoma | Phase 1 | Terminated | Celularity Incorporated | 3 | 2020-10-01 | 2022-08-10 |
| Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 CYNK-001 - Coronavirus, Coronavirus Infection | Phase 1 / Phase 2 | Terminated | Celularity Incorporated | 7 | 2020-09-02 | 2026-06-26 |
| Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma CYNK-001 - Multiple Myeloma, Neoplasm, Plasma Cell | Phase 1 | Unknown | Celularity Incorporated | 29 | 2020-05-12 | 2023-02-16 |
| Natural Killer Cell (CYNK-001) Infusions in Adults with AML CYNK-001 - Leukemia, Leukemia, Myeloid | Phase 1 | Terminated | Celularity Incorporated | 27 | 2020-03-12 | 2024-12-12 |
| Mentholated Cream Containing Oxygenated Glycerol Triesters on Acute Pain of the Muscles and Joints Mentholated Cream, Mentholated Cream with OGT - Pain, Analgesics | Phase 1 / Phase 2 | Completed | NEMA Research, Inc. | 71 | 2007-05-01 | 2011-07-06 |
Hematologic Diseases (2) · Immune System Diseases (2) · Neoplasm, Residual (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Acute Pain (1) · Blood Protein Disorders (1) · COVID-19 (1) · Cardiovascular Diseases (1) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Glioblastoma (1) · Hematologic Neoplasms (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1)
Pathological Conditions, Signs and Symptoms (3) · Hemic and Lymphatic Diseases (2) · Neoplastic Processes (2) · Pathologic Processes (2) · Astrocytoma (1) · Chemically-Induced Disorders (1) · Glioma (1) · Infections (1) · Lymphatic Diseases (1) · Mental Disorders (1) · Muscular Diseases (1) · Musculoskeletal Diseases (1) · Narcotic-Related Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
Buprenorphine, Naloxone Drug Combination (1) · UDP-N-acetylglucosamine-peptide beta-N-acetylglucosaminyltransferase (1) · lemborexant (1)
Celularity Incorporated (4) · NEMA Research, Inc. (1) · Virginia Commonwealth University (1)
United States (5)
Adrian Kilcoyne, MD (1) · Barry T Reece, MS, MBA (1) · Corey Casper, MD MPH (1) · Frederick G Moeller, MD (1) · Jessica Williams, BS (1) · Sharmila Koppisetti, M.D (1) · Sharmila Koppisetti, MD (1)
UG1DA050207 (1)